Apellis logo.jpg
Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy
September 04, 2018 07:30 ET | Apellis Pharmaceuticals, Inc.
PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of Anemia in PNH Patients on Soliris™ CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 04, 2018 ...
Apellis logo.jpg
Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™
June 26, 2018 17:00 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., and WALTHAM Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis logo.jpg
Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 26, 2018 07:30 ET | Apellis Pharmaceuticals, Inc.
Severely anemic patients with PNH on treatment with Soliris™ can become transfusion-free with improved hemoglobin when switched to APL-2 monotherapy Treatment-naïve patients with PNH show clinically...
Mean LDH
Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab
April 16, 2018 09:23 ET | Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Achillion-Logo-150 (4).jpg
CORRECTION - Achillion Pharmaceuticals, Inc.
December 20, 2017 12:12 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- In the news release issued earlier today by Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), please be advised the headline should read "Achillion...
Achillion-Logo-150 (4).jpg
Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
December 20, 2017 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the...
Achillion-Logo-150 (4).jpg
Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 01, 2017 16:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended September 30, 2017. For the third...
Achillion-Logo-150 (4).jpg
USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor
October 24, 2017 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. Patent to...
Akari Logo (1).jpg
Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
September 19, 2017 07:00 ET | Akari Therapeutics, Plc
NEW YORK and LONDON, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, is pleased to announce its Chief Executive...
Achillion-Logo-150 (4).jpg
Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor
August 08, 2017 16:01 ET | Achillion Pharmaceuticals, Inc.
- Interim results demonstrate ability of ACH-4471 to reduce LDH and improve hemoglobin and fatigue scores in patients with untreated PNH - - Global program expansion planned in PNH, C3G and IC-MPGN -...